{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T23:01:18Z","timestamp":1782774078475,"version":"3.54.5"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2009,10,7]],"date-time":"2009-10-07T00:00:00Z","timestamp":1254873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2009,10,7]],"date-time":"2009-10-07T00:00:00Z","timestamp":1254873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatology"],"abstract":"<jats:p>Background: Several neoplasms including cutaneous T-cell lymphomas, malignant melanoma and Kaposi\u2019s sarcoma have been successfully treated with systemic or intralesional interferons (IFNs). Recently, intralesional \u03b1-IFN has also been employed in the treatment of basal cell carcinoma (BCC). Objective: The aim of our study was to evaluate the efficacy of IFN alfa-2b in the treatment of BCC. Methods: 140 patients with BCC were treated with intra- und perilesional injections of recombinant IFN alfa-2b at a dosage of 1.5\u20133 \u00d7 106 IU, three times a week for 4\u20138 weeks. Results: Complete response was achieved in 94 patients (67.1%), partial response in 33 patients (23.6%) and no response in 13 patients (9.3%). Side effects included fever, headache, fatigue and nausea but were reversible with the use of paracetamol. None of the patients discontinued therapy due to side effects. After a mean follow-up period of 36 months (12\u201354 months) no relapse has been observed. Conclusion: Based on our results, intra- and perilesional IFN alfa-2b represents an effective, alternative treatment for BCC.<\/jats:p>","DOI":"10.1159\/000246688","type":"journal-article","created":{"date-parts":[[2009,10,7]],"date-time":"2009-10-07T07:08:20Z","timestamp":1254899300000},"page":"214-217","source":"Crossref","is-referenced-by-count":41,"title":["Use of Recombinant Interferon Alfa-2b in the Treatment of Basal Cell Carcinoma"],"prefix":"10.1159","author":[{"given":"S.","family":"Chimenti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Peris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Di Cristofaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Fargnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Torlone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2009,10,7]]},"container-title":["Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/246688","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000246688","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T09:18:19Z","timestamp":1777540699000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000246688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,7]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000246688","archive":["Portico"],"relation":{},"ISSN":["1018-8665","1421-9832"],"issn-type":[{"value":"1018-8665","type":"print"},{"value":"1421-9832","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,7]]}}}